Comparison of Pre- and Postoperative IOP in TriamcinoloneAssisted Vitrectomy Patients with and without Lens Surgery

Research

Authors

  • Ade John Nursalim Department of Ophthalmology, RS Kandou Hospital, Sam Ratulangi University, Manado, Indonesia
  • Vera Sumual Department of Ophthalmology, RS Kandou Hospital, Sam Ratulangi University, Manado, Indonesia
  • Ardelia Emily Wulur Ophthalmology Resident, Sam Ratulangi University, Manado, Indonesia

DOI:

https://doi.org/10.55175/cdk.v52i7.1592

Keywords:

Intraocular pressure, triamcinolone, vitrectomy, vitreoretinal surgery

Abstract

Introduction: This retrospective study evaluates the impact of triamcinolone-assisted vitrectomy on intraocular pressure (IOP) in patients undergoing vitreoretinal surgery, with particular focus on comparing outcomes in patients with and without lens surgery. Methods: Medical records of patients treated at R.D. Kandou Hospital from May 2019 to May 2024 were reviewed, and pre- and postoperative IOP values were analyzed. A total of 35 patients met the inclusion criteria. Results: The results show a significant reduction in IOP at all postoperative intervals, with mean differences of 11.12 mmHg at 1 day, 8.60 mmHg at 1 week, 13.23 mmHg at 1 month, and 16.91 mmHg at 3 months postoperatively. Analysis revealed no significant difference in IOP outcomes between phakic and pseudophakic patients. Conclusion: These findings indicate that triamcinolone-assisted vitrectomy effectively lowers IOP, regardless of lens status.

Downloads

Download data is not yet available.

References

Kampougeris G, Cheema R, McPherson R, Gorman C. Safety of triamcinolone acetonide (TA)-assisted pars plana vitrectomy in macular hole surgery. Eye. 2007;21(5):591-4. DOI: 10.1038/sj.eye.6702265.

Sakamoto T, Miyazaki M, Hisatomi T, Nakamura T, Ueno A, Itaya K, et al. Triamcinolone-assisted pars plana vitrectomy improves the surgical procedures and decreases the postoperative blood–ocular barrier breakdown. Graefe's Arch Clin Experiment Ophthalmol. 2002;240:423-9. DOI: 10.1007/s00417-002-0454-2.

Aceves-Franco LA, Sanchez-Aguilar OE, Barragan-Arias AR, Ponce-Gallegos MA, Navarro-Partida J, Santos A. The evolution of triamcinolone acetonide therapeutic use in retinal diseases: From off-label intravitreal injection to advanced nano-drug delivery systems. Biomedicines 2023;11(7):1901. DOI: 10.3390/biomedicines11071901.

Farah ME, Rodrigues EB, Maia A, Magalhaes JR O, Lima A. Vital dyes for staining intraocular membranes and tissues during citrectomy. Retina Today [Internet]. 2010 Jul-Aug;28-32. Available from: https://retinatoday.com/articles/2010-july-aug/vital-dyes-for-staining-intraocular-membranes-and-tissues-during-vitrectomy.

Sakamoto T, Ishibashi T. Visualizing vitreous in vitrectomy by triamcinolone. Graefe's Arch Clin Experiment Ophthalmol. 2009;247:1153-63. DOI: 10.1007/s00417-009-1118-2.

Park HY, Yi K, Kim HK. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Korean J Ophthalmol. 2005;19(2):122-7. DOI: 10.3341/kjo.2005.19.2.122.

Kiddee W, Trope GE, Sheng L, Beltran-Agullo L, Smith M, Strungaru MH, et al. Intraocular pressure monitoring post intravitreal steroids: A systematic review. Survey Ophthalmol. 2013;58(4):291-310. DOI: 10.1016/j.survophthal.2012.08.003.

Wykrota AA, Abdin AD, Munteanu C, Low U, Seitz B. Incidence and treatment approach of intraocular pressure elevation after various types of local steroids for retinal diseases. Graefe's Arch Clin Experiment Ophthalmol. 2023;261(12):3569-79. DOI: 10.1007/s00417-023-06163-5.

Gillies MC, Simpson JM, Billson FA, Luo W, Penfold P, Chua W, et al. Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. Arch Ophthalmol. 2004;122(3):336-40. DOI: 10.1001/archopht.122.3.336.

Jonas JB, Degenring RF, Kreissig I, Akkoyun I, Kamppeter BA. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology 2005;112(4):593-8. DOI: 10.1016/j.ophtha.2004.10.042.

Parke III DW, Sisk RA, Houston SK, Murray TG. Ocular hypertension after intravitreal triamcinolone with vitrectomy and phacoemulsification. Clin Ophthalmol. 2012:925-31. DOI: 10.2147/OPTH.S32934.

Jonas JB. Intravitreal triamcinolone acetonide: A change in a paradigm. Ophthalmic Res. 2006;38(4):218-4510.1159/000093796. DOI: 10.1159/000093796.

Shrivastava A, Singh K. The impact of cataract surgery on glaucoma care. Curr Opin Ophthalmol. 2014;25(1):19-25. DOI: 10.1097/ICU.0000000000000010.

Allam G, Ellakkany R, Ellayeh A, Mohsen T, Abouelkheir HE, Gaafar W. Outcome of pediatric cataract surgery with intraocular injection of triamcinolone acetonide: Randomized controlled trial. Eur J Ophthalmol. 2018;28(6):633-8. DOI: 10.1177/1120672117754168.

Yamakiri K, Sakamoto T, Noda Y, Nakahara M, Ogino N, Kubota T, et al. One-year results of a multicenter controlled clinical trial of triamcinolone in pars plana vitrectomy. Graefe's Arch Clin Experiment Ophthalmol. 2008;246:959-66. DOI: 10.1007/s00417-008-0829-0.

Hollands H, Seif G, Hollands S, Gale J. A trial of topical prednisolone acetate before intravitreal triamcinolone acetonide decreases intraocular pressure spikes. Canad J Ophthalmol. 2010;45(5):484-8. DOI: 10.3129/i10-050.

Koval MS, Moster MR, Freidl KB, Waisbourd M, Jain SG, Ichhpujani P, et al. Intracameral triamcinolone acetonide in glaucoma surgery: A prospective randomized controlled trial. Am Jf Ophthalmol. 2014;158(2):395-401. e2. DOI: 10.1016/j.ajo.2014.04.027.

Slabaugh MA, Bojikian KD, Moore DB, Chen PP. Reply: Intraocular pressure spike prophylaxis in glaucoma patients 1 day after phacoemulsification. J Cataract Refractive Surg. 2014;40(6):1055-6. DOI: 10.1016/j.jcrs.2014.05.001.

Parekh A, Srivastava S, Bena J, Albini T, Nguyen QD, Goldstein DA. Risk factors associated with intraocular pressure in patients with uveitis treated with the fluocinolone acetonide implant. JAMA Ophthalmol. 2015;133(5):568-73. DOI: 10.1001/jamaophthalmol.2015.51.

Ren Y, Du S, Zheng D, Shi Y, Pan L, Yan H. Intraoperative intravitreal triamcinolone acetonide injection for prevention of postoperative inflammation and complications after phacoemulsification in patients with uveitic cataract. BMC Ophthalmol. 2021;21(1):245. DOI: 10.1186/s12886-021-02017-y.

Grzybowski A, Kanclerz P. Do we need day-1 postoperative follow-up after cataract surgery? Graefe's Arch Clin Experiment Ophthalmol. 2019;257:855-61. DOI: 10.1007/s00417-018-04210-0.

Baudouin C, Kolko M, Melik-Parsadaniantz S, Messmer EM. Inflammation in glaucoma: From the back to the front of the eye, and beyond. Progr Retinal Eye Res. 2021;83:100916. DOI: 10.1016/j.preteyeres.2020.100916.

Couch SM, Bakri SJ. Intravitreal triamcinolone for intraocular inflammation and associated macular edema. Clin Ophthalmol. 2009;3:41-7. DOI: 10.2147/opth.s4477.

Chieh JJ, Roth DB, Liu M, Belmont J, Nelson M, Regillo C, et al. Intravitreal triamcinolone acetonide for diabetic macular edema. Retina. 2005;25(7):828-34. DOI: 10.1097/00006982-200510000-00002.

Ricker LJ, Kessels AG, de Jager W, Hendrikse F, Kijlstra A, la Heij EC. Prediction of proliferative vitreoretinopathy after retinal detachment surgery: potential of biomarker profiling. Am J Ophthalmol. 2012;154(2):347-54. e2. DOI: 10.1016/j.ajo.2012.02.004.

Bonfiglio V, Reibaldi M, Fallico M, Russo A, Pizzo A, Fichera S, et al. Widening use of dexamethasone implant for the treatment of macular edema. Drug design, Development and Therapy 2017;11:2359-72. DOI: 10.2147/DDDT.S138922.

Lusthaus JA, McCluskey PJ, Martin KR. Intraocular pressure spikes following iStent inject and the relationship to aqueous outflow in open angle glaucoma. J Glaucoma. 2023;32(7):600-8. DOI: 10.1097/IJG.0000000000002195.

Byrne S, Ng J, Hildreth A, Danjoux JP, Steel DH. Refractive change following pseudophakic vitrectomy. BMC Ophthalmol. 2008;8:1-6. DOI: 10.1186/1471-2415-8-19.

Liao M, Huang Y, Wang J, Meng X, Liu Y, Yu J, et al. Long-term outcomes of administration of intravitreal triamcinolone acetonide after posterior vitreous detachment during pars plana vitrectomy for proliferative diabetic retinopathy. Br J Ophthalmol. 2023;107(4):560-410. DOI: 10.1136/bjophthalmol-2021-320332.

Kumagai K, Furukawa M, Ogino N, Larson E, Uemura A. Long-term outcomes of macular hole surgery with triamcinolone acetonide–assisted internal limiting membrane peeling. Retina 2007;27(9):1249-54. DOI: 10.1097/IAE.0b013e3180ed45cc.

Dada T, Dhawan M, Garg S, Nair S, Mandal S. Safety and efficacy of intraoperative intravitreal injection of triamcinolone acetonide injection after phacoemulsification in cases of uveitic cataract. J Cataract Refractive Surg. 2007;33(9):1613-810. DOI: 10.1016/j.jcrs.2007.04.029.

Jampol LM, Yannuzzi LA, Weinreb RN. Glaucoma and intravitreal steroids. Ophthalmology 2005;112(8):1325-610. DOI: 1016/j.ophtha.2005.03.008.

Wang B, Dong N, Xu B, Liu J, Xiao L. Efficacy and safety of intracameral triamcinolone acetonide to control postoperative inflammation after phacotrabeculectomy. J Cataract Refractive Surg. 2013;39(11):1691-710. DOI: 10.1016/j.jcrs.2013.04.042.

Dyer D, Callanan D, Bochow T, Abraham P, Lambert HM, Lee SY, et al. Clinical evaluation of the safety and efficacy of preservative-free triamcinolone (Tiresence® [Triamcinolone acetonide injetable suspension] 40 mg/ml) for visualization during pars plana vitrectomy. Retina. 2009;29(1):38-4510. DOI: 10.1097/IAE.0b013e318188c6e2.

Bonanomi MTBC, Susanna R. Intravitreal triamcinolone acetonide as adjunctive treatment for neovascular glaucoma. Clinics. 2005;60(4):347-50. DOI: 10.1590/S1807-59322005000400014.

Downloads

Published

07-07-2025

How to Cite

Nursalim, A. J., Sumual, V., & Wulur, A. E. (2025). Comparison of Pre- and Postoperative IOP in TriamcinoloneAssisted Vitrectomy Patients with and without Lens Surgery: Research. Cermin Dunia Kedokteran, 52(7), 449–455. https://doi.org/10.55175/cdk.v52i7.1592